Please note, this OEL/ADE monograph also applies to pravastatin sodium (CAS RN 81131-70-6). Pravastatin is indicated to treat high blood lipid levels and prevent cardiovascular diseases and stroke. Pravastatin sodium is a competitive HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor that decreases intracellular cholesterol levels through reversible inhibition of HMG-CoA reductase activity. This reduction in cholesterol leads to an increased low-density lipoprotein (LDL)-receptors, improved receptor-mediated catabolism and clearance of circulating LDL. It also blocks the production of LDL by inhibiting the synthesis of its precursor, very low-density lipoprotein (VLDL), in the liver.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Pravastatin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.